|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Iteos Therapeutics, Inc. (ITOS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
37,960,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile iTeos Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of a differentiated immuno-oncology therapeutics for patients. Co.'s product candidate, inupadenant, is designed as a selective small molecule antagonist of the adenosine A2a receptor, in the adenosine pathway, a main driver of immunosuppression in the tumor microenvironment across a range of tumors. Co.'s main antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains, an immune checkpoint with multiple mechanisms of action leading to immunosuppression.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
5,000 |
5,000 |
Total Buy Value |
$0 |
$0 |
$41,850 |
$41,850 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
350,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$5,692,673 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mcgrath Yvonne |
VP, Research and Development |
|
2021-05-24 |
4 |
S |
$21.92 |
$173,796 |
D/D |
(7,927) |
0 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-05-24 |
4 |
OE |
$4.23 |
$33,531 |
D/D |
7,927 |
7,927 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-05-17 |
4 |
AS |
$24.41 |
$195,719 |
D/D |
(7,926) |
0 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-05-17 |
4 |
OE |
$4.23 |
$33,527 |
D/D |
7,926 |
7,926 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-04-09 |
4 |
AS |
$29.99 |
$3,569 |
I/I |
(119) |
3,665,787 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2021-04-09 |
4 |
AS |
$29.99 |
$5,998 |
I/I |
(200) |
6,004,368 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-04-09 |
4 |
AS |
$29.99 |
$3,569 |
I/I |
(119) |
3,665,787 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-04-08 |
4 |
AS |
$30.51 |
$589,089 |
I/I |
(19,304) |
3,655,906 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2021-04-08 |
4 |
AS |
$30.51 |
$985,802 |
I/I |
(32,304) |
6,004,568 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-04-08 |
4 |
AS |
$30.51 |
$589,089 |
I/I |
(19,304) |
3,655,906 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$0.00 |
$0 |
I/I |
(15,670) |
3,685,210 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$32.07 |
$188,254 |
I/I |
(5,783) |
3,700,880 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$0.00 |
$0 |
I/I |
(15,670) |
6,036,872 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$32.07 |
$315,048 |
I/I |
(9,678) |
6,052,542 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$0.00 |
$0 |
I/I |
(15,670) |
3,685,210 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$32.07 |
$188,254 |
I/I |
(5,783) |
3,700,880 |
|
- |
|
Oncology Impact Fund (cayman) Management L.p. |
X* |
|
2020-07-28 |
4 |
B |
$19.00 |
$6,080,000 |
I/I |
320,000 |
2,355,557 |
0.01 |
- |
|
Oncology Impact Fund (cayman) Management L.p. |
X* |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
5,742,220 |
2,195,557 |
|
- |
|
Davis Aaron I. |
Director |
|
2020-07-28 |
4 |
B |
$19.00 |
$27,075,000 |
I/I |
1,425,000 |
72,243 |
2.25 |
- |
|
Davis Aaron I. |
Director |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
2,992,259 |
48,691 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2020-07-28 |
4 |
B |
$19.00 |
$3,040,000 |
I/I |
160,000 |
25,974 |
1.5 |
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
3,546,663 |
24,853 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2020-07-28 |
4 |
B |
$19.00 |
$3,040,000 |
I/I |
160,000 |
25,974 |
1.5 |
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
3,546,663 |
24,853 |
|
- |
|
Mva Investors, Llc |
10% Owner |
|
2020-07-28 |
4 |
B |
$19.00 |
$27,075,000 |
D/D |
1,425,000 |
72,243 |
2.45 |
- |
|
229 Records found
|
|
Page 9 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|